View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 10, 2019updated 12 Jul 2022 11:59am

Abeona to initiate Phase III trial of EB-101 to treat RDEB

Abeona Therapeutics is ready to initiate its pivotal Phase III clinical trial, VIITAL, to evaluate EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).

Abeona Therapeutics is ready to initiate its pivotal Phase III clinical trial, VIITAL, to evaluate EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The move comes after the US Food and Drug Administration (FDA) removed its clinical hold and provided clearance for the study following the submission of additional data points by Abeona on the transport stability of EB-101 to clinical sites.

Abeona expects to initiate the VIITAL study of the autologous, gene-corrected cell therapy EB-101 during the first quarter of next year.

Abeona Therapeutics CEO João Siffert said: “Recently published long-term follow-up data from our Phase I/II trial leaves us increasingly confident that EB-101 can provide durable healing for large, chronic wounds that afflict many RDEB patients.

“The success in building and qualifying a state-of-the-art GMP manufacturing facility also represents a critical step toward bringing this novel product to patients in dire need of effective treatment.”

The multi-centre, randomised VIITAL Phase III trial will evaluate EB-101 in ten to 15 RDEB patients, with approximately 30 chronic wound sites treated in total.

The trial’s primary endpoint will be the proportion of wounds with a greater than 50% healing at three months compared to untreated wound sites on the same patient.

Secondary endpoints of the study include the patient’s global impression of change in pain from baseline, as well as other patient-reported outcomes assessing pain during dressing changes, pain impact and physical function.

Data from a Stanford University Phase I/II trial that evaluated EB-101 based on two to five years of follow-up showed that EB-101 provided durable wound healing for RDEB patients.

RDEB is a rare connective tissue disorder characterised by severe skin wounds that cause pain and can lead to systemic complications.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena